bioRxivMicrobiologyPreprint
Engineered human mesenchymal stem cells as new vaccine platform for COVID-19
Abstract
Recently, there are several routes for COVID-19 vaccine research, yet their weaknesses lie in low efficiency, tolerability, immune adaptability and safety. We describe a new approach to COVID-19 based on engineered human mesenchymal stem cells(hu-MSC), which is like a small protein antigen response device, but will be gradually cleared and degraded by bodys immune system among recognization process. The antibody response results show that this is effective and fast. Furthermore, after several antibody response tests, we obtained an injection of a set of cocktail-like modified human mesenchymal stem cell line. This strategy opened a new avenue for vaccine design against COVID-19.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Novel CRISPR-Engineered, Stem Cell-Derived Cellular Vaccine
K. Chakraborty, A. Chandrashekar, … T. Henley·bioRxiv·Dec 28, 2021
- A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine
Cindy Hoerner, Christoph Schuermann, … Michael D Muehlebach·bioRxiv·Jul 11, 2020
- Engineered Migrasomes: Harnessing Core Migrasome Machinery and Hypotonic Shock to Develop a Robust and Thermally Stable Vaccine Platform
Dongju Wang, Haifang Wang, … Zhihua Liu·bioRxiv·Mar 13, 2024
- Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates
K. V. Kalnin, T. Plitnik, … D. Casimiro·bioRxiv·Oct 14, 2020
- Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters
Neil C. Dalvie, Sergio A. Rodriguez‐Aponte, … John Christopher Love·bioRxiv·Mar 3, 2021
- The Dual-Antigen Ad5 COVID-19 Vaccine Delivered as an Intranasal Plus Subcutaneous Prime Elicits Th1 Dominant T-Cell and Humoral Responses in CD-1 Mice
A. Rice, M. Verma, … P. Soon-Shiong·bioRxiv·Mar 22, 2021